Citius Pharmaceuticals Inc
$ 0.57
3.56%
11 Jun - close price
- Market Cap 15,120,900 USD
- Current Price $ 0.57
- High / Low $ 0.59 / 0.55
- Stock P/E N/A
- Book Value 2.75
- EPS -2.14
- Next Earning Report 2026-08-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.84 %
- 52 Week High 2.48
- 52 Week Low 0.48
About
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. The company is headquartered in Cranford, New Jersey.
Analyst Target Price
$4.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-02-13 | 2025-12-25 | 2025-08-12 | 2025-05-14 | 2025-01-03 | 2024-12-27 | 2024-08-12 | 2024-05-14 | 2024-02-14 | 2023-12-29 | 2023-08-14 |
| Reported EPS | -0.95 | -0.38 | -0.11 | -0.8 | -1.27 | -1.3 | -5.8 | -1.5 | -1.25 | -0.06 | -1.75 | -1.5 |
| Estimated EPS | -0.32 | -0.3 | -0.24 | -0.21 | 0.11 | -1.25 | -1.5 | -1.12 | -1.5 | 0.13 | -1.5 | -1.75 |
| Surprise | -0.63 | -0.08 | 0.13 | -0.59 | -1.38 | -0.05 | -4.3 | -0.38 | 0.25 | -0.19 | -0.25 | 0.25 |
| Surprise Percentage | -196.875% | -26.6667% | 54.1667% | -280.9524% | -1254.5455% | -4% | -286.6667% | -33.9286% | 16.6667% | -146.1538% | -16.6667% | 14.2857% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CTXR
2026-06-04 11:40:11
This article provides a stock analysis of Citius Pharmaceuticals (Nasdaq:CTXR), highlighting its current market capitalization, analyst price target indicating it's undervalued, and projected earnings growth. It also delves into various risks, including share price volatility, shareholder dilution, and cash runway concerns, alongside recent updates on clinical trials and equity offerings.
2026-06-03 10:10:34
This SEC filing for Citius Pharmaceuticals, Inc. (CTXR) is an "EFFECT" filing, indicating a Notice of Effectiveness for an S-3 form with an effective date of June 2, 2026, at 4:15 P.M. The filing detail includes the company's CIK and file number. The impact and sentiment of this filing are rated as neutral.
2026-06-02 23:10:23
MarketBeat provides an overview of Citius Pharmaceuticals' (CTXR) SEC filings, including its 10K forms, 10Q reports, and 8K current reports. The article details how investors can use these publicly available documents to evaluate the company's financial health, with the most recent filing being a Form SCHEDULE 13D/A on June 4, 2026. It also explains the significance and differences between various SEC filing types.
2026-06-01 20:40:18
Citius Oncology (NASDAQ: CTXR) announced early Phase 1 data for LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab in recurrent or refractory gynecologic cancers. The study, involving 21 efficacy-evaluable patients, showed a 48% clinical benefit rate and a median progression-free survival of 20.5 months in that subgroup despite patients being heavily pre-treated. While promising, the company emphasized that LYMPHIR's use in gynecologic malignancies remains investigational and is not FDA-approved for this indication, with a Phase 2 expansion study being planned.
2026-05-28 11:39:56
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is projected to reach breakeven within just over a year, with analysts forecasting a final loss in 2026 before generating positive profits of US$27m in 2027. This profitability hinges on an average annual growth rate of 56%. The company, with a US$19m market-cap, reported a US$46m loss in its latest trailing-twelve-month results but uniquely operates without any debt on its balance sheet.
2026-05-26 11:40:33
Citius Oncology announced that data from an investigator-initiated Phase 1 study of LYMPHIR® in combination with pembrolizumab for relapsed/refractory gynecologic malignancies will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study showed a 24% objective response rate, an average duration of response of 21.1 months in responders, and a favorable safety profile, suggesting LYMPHIR's potential to enhance immune checkpoint inhibitor efficacy. This presentation highlights LYMPHIR's broader therapeutic potential beyond its current indication for cutaneous T-cell lymphoma (CTCL).
